Porcine Reproductive and Respiratory Syndrome Vaccine Market Analysis-2027


Posted June 11, 2021 by SANJAYCMI

“Coherent Market Insights “PORCINE REPRODUCTIVE AND RESPIRATORY SYNDROME VACCINE MARKET – GLOBAL TRENDS, ESTIMATES AND FORECASTS, 2020-2027″
 
Porcine Reproductive and Respiratory Syndrome Vaccine Market, By Product Type (Modified Live Virus Vaccine, Inactivated Vaccine, and Subunit Vaccines), By Route of Administration (Intramuscular and Intradermal), By Virus Genotype (Type I and Type II), By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Global Industry Insights, Trends, Outlooks, and Opportunity Analysis, 2019-2027

Porcine reproductive and respiratory syndrome (PRRS) is a viral disease which causes various reproductive problems such as late term abortions, infertility, weak and still born piglets in sows and respiratory problems like labored breathing, fever and pneumonia in pigs of all age group. Porcine reproductive and respiratory syndrome virus (PRRSV) is contagious which can be transmitted by infectious aerosols or direct contact.

Porcine reproductive and respiratory syndrome vaccines prevent the pigs from acquiring this syndrome. The vaccine is developed on the basis of two genotypes of the virus; Type I (European) and Type II (North American) and can be administered through intramuscular route or intradermal route.

* The sample copy includes: Report Summary, Table of Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.

Request a sample copy of this report: https://www.coherentmarketinsights.com/insight/request-sample/3285

Global Porcine Reproductive and Respiratory Syndrome Vaccine Market Dynamics

An increasing demand for pork meat is expected to propel the market growth over the forecast period. According to the U.S Department of Agriculture - Foreign Agricultural Service (USDA – FAS), 2017, among the total meat consumption nearly 40.4% of pork meat is consumed globally.

Moreover, significant economic losses to swine producers caused by the porcine reproductive and respiratory virus is expected to propel the market growth. For instance, according to the statistics presented in the North American PRRS Symposium held in November 2019, an around 62% out of total economic loss was reported in the pork meat production market, which is US$ 581 million, has occurred in the growing period of the pigs due to the porcine reproductive and respiratory virus.

Global Porcine Reproductive and Respiratory Syndrome Vaccine Market - Regional Insights

North America accounted for the largest market share in 2018 owing to launch and approval of new vaccines for the porcine reproductive and respiratory syndrome in the region. For instance, in June 2018, Elanco Animal Health, a division of Eli Lily and Company, introduced a modified live respiratory vaccine, Prevacent PRRS to reduce the porcine reproductive and respiratory syndrome (PRRS), respiratory form, in two weeks or older piglets. Similarly, in 2018, MSD Animal Health launched a needle free device, IDAL 3G, with two injector heads for intradermal vaccination.

Browse Research Report: https://www.coherentmarketinsights.com/ongoing-insight/porcine-reproductive-and-respiratory-syndrome-vaccine-market-3285

1The device makes the vaccine administration a safer and less stressful procedure for the pigs and more efficient and convenient for farmers. The device is used to administer vaccines like PORCILIS PRRS, for porcine reproductive and respiratory syndrome virus and PORCILIS PCV ID, for porcine circovirus type 2 simultaneously.

Global Porcine Reproductive and Respiratory Syndrome Vaccine Market - Competitive Landscape

Key players operating in the porcine reproductive and respiratory syndrome vaccine market include Boehringer-Ingelheim GmbH, Zoetis, MSD Animal Health, Bioveta, Phibro Animal Health, Ceva , Ascent Corporation, Agrovet, Winsun Bio, Konipharm, Merck & Co., Inc., Elanco (Eli Lily and Company), and Ringpu (Tianjin) Bio-Pharmacy Co., Ltd.

Moreover, key players in the market are focused on developing new products in order to enhance their market share. For instance, in October 2019, Boehringer-Ingelheim launched Reprocyc ParvoFLEX, a subunit vaccine for the swine fetuses to protect them from the transplacental infections caused by porcine parovirus.

Buy-Now this research report: https://www.coherentmarketinsights.com/insight/buy-now/3285

About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:
mailto:[email protected]
U.S. Office:
Name: Mr. Shah
Coherent Market Insights 1001 4th Ave,
# 3200 Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN : +050-5539-1737
-- END ---
Contact Email [email protected]
Issued By Coherent Market Insights
Phone +1-206-701-6702
Business Address 1001 4th Ave
# 3200 Seattle, WA 98154, U.S.
Country United States
Categories Health , Marketing , Research
Tags Porcine Reproductive and Respiratory Syndrome Vaccine Market Overview , Porcine Reproductive and Respiratory Syndrome Vaccine , Porcine Reproductive and Respiratory Syndrome Vaccine Market
Last Updated June 11, 2021